Mirant settles price-reporting charges

Atlanta-based energy company Mirant has settled charges with the US Commodity Futures Trading Commission (CFTC) of false reporting of natural gas prices.

The commission charged that traders at Mirant subsidiary Mirant Americas Energy Marketing (MAEM) had made false reports to gas price compilers from January 2000 to December 2001, and has ordered the company to pay a penalty of $12.5 million.

MAEM elected to settle with the CFTC to avoid the expense, distraction and risk of litigation and enable the company’s resources to remain fully focused on Chapter 11 emergence, said Doug Miller, Mirant’s general counsel.

Under the terms of the settlement, MAEM neither admitted nor denied the allegations that its employees reported false information in an attempt to manipulate pricing.

The false reports submitted by MAEM included false price, volume and/or counterparty information concerning natural gas cash transactions, as well as information concerning fictitious trades and/or trades observed in the market, alleged the CFTC. The information could have affected prices of New York Mercantile Exchange natural gas futures contracts, added the commission.

Price and volume information is used by price compilers to calculate published indexes of natural gas prices for various natural gas hubs throughout the US. The price compilers in this case were Gas Daily, Inside Ferc and Natural Gas Intelligence.

In 2002, Mirant had reviewed and amended its external reporting process following industry-wide natural gas reporting problems, said Miller. MAEM now requires all data provided to indexes to be validated and conveyed by risk management staff reporting to the company’s chief risk officer, rather than by MAEM personnel, he added.

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here